NextBigFuture

First phase 1 human aging reversal trials (GDF, Myostatin) in a year or two and George Church discusses how to affordably rejuvenate the whole body

The new goal is to reverse aging, not only in animals, but in humans. And age reversal is essential, as significant age-related disruption has already occurred in most people due to changes in our ...
Business Wire

PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent ...

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies ...
Business Wire

PhaseBio Announces Dosing of First Patient in European Union as Part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor

PhaseBio initiated the REVERSE-IT trial, a pivotal Phase 3 clinical trial of bentracimab, in March 2020 to support a Biologics License Application for bentracimab in both major bleeding and urgent ...
Nasdaq

PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of the Antiplatelet Effects of Ticagrelor

Cardiovascular disease remains a leading cause of mortality in both Canada and globally; the lack of reversal agents for patients taking antiplatelet therapies who require urgent surgery or experience ...
FierceBiotech

Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Bayer and Janssen for Phase 3 Studies of Andexanet Alfa*, Investigational Factor Xa Inhibitor Reversal ...

SOUTH SAN FRANCISCO, Calif., Feb. 3, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (PTLA) today announced that it has entered into a second clinical collaboration agreement with Bayer HealthCare ...
FierceBiotech

Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3 ANNEXA-A(TM) Study Demonstrating That Investigational Andexanet Alfa Sustained Reversal ...

SOUTH SAN FRANCISCO, Calif., PRINCETON, N.J. and NEW YORK, June 22, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (PTLA), Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) today announced ...